These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 32752193)
1. Epigenetic Targeting of Mcl-1 Is Synthetically Lethal with Bcl-xL/Bcl-2 Inhibition in Model Systems of Glioblastoma. Shang E; Nguyen TTT; Shu C; Westhoff MA; Karpel-Massler G; Siegelin MD Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32752193 [TBL] [Abstract][Full Text] [Related]
2. Dual Inhibition of Bcl-2/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems. Shang E; Zhang Y; Shu C; Ishida CT; Bianchetti E; Westhoff MA; Karpel-Massler G; Siegelin MD Sci Rep; 2018 Oct; 8(1):15383. PubMed ID: 30337641 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of Bcl-2/Bcl-xL and c-MET causes synthetic lethality in model systems of glioblastoma. Zhang Y; Ishida CT; Shu C; Kleiner G; Sanchez-Quintero MJ; Bianchetti E; Quinzii CM; Westhoff MA; Karpel-Massler G; Siegelin MD Sci Rep; 2018 May; 8(1):7373. PubMed ID: 29743557 [TBL] [Abstract][Full Text] [Related]
5. TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo. Karpel-Massler G; Bâ M; Shu C; Halatsch ME; Westhoff MA; Bruce JN; Canoll P; Siegelin MD Oncotarget; 2015 Nov; 6(34):36456-71. PubMed ID: 26474387 [TBL] [Abstract][Full Text] [Related]
6. Increased apoptotic sensitivity of glioblastoma enables therapeutic targeting by BH3-mimetics. Koessinger AL; Cloix C; Koessinger D; Heiland DH; Bock FJ; Strathdee K; Kinch K; Martínez-Escardó L; Paul NR; Nixon C; Malviya G; Jackson MR; Campbell KJ; Stevenson K; Davis S; Elmasry Y; Ahmed A; O'Prey J; Ichim G; Schnell O; Stewart W; Blyth K; Ryan KM; Chalmers AJ; Norman JC; Tait SWG Cell Death Differ; 2022 Oct; 29(10):2089-2104. PubMed ID: 35473984 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of Mitochondrial Matrix Chaperones and Antiapoptotic Bcl-2 Family Proteins Empower Antitumor Therapeutic Responses. Karpel-Massler G; Ishida CT; Bianchetti E; Shu C; Perez-Lorenzo R; Horst B; Banu M; Roth KA; Bruce JN; Canoll P; Altieri DC; Siegelin MD Cancer Res; 2017 Jul; 77(13):3513-3526. PubMed ID: 28522750 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of HDAC1/2 Along with TRAP1 Causes Synthetic Lethality in Glioblastoma Model Systems. Nguyen TTT; Zhang Y; Shang E; Shu C; Quinzii CM; Westhoff MA; Karpel-Massler G; Siegelin MD Cells; 2020 Jul; 9(7):. PubMed ID: 32664214 [TBL] [Abstract][Full Text] [Related]
9. Combined inhibition of Bcl-2/Bcl-xL and Usp9X/Bag3 overcomes apoptotic resistance in glioblastoma in vitro and in vivo. Karpel-Massler G; Shu C; Chau L; Banu M; Halatsch ME; Westhoff MA; Ramirez Y; Ross AH; Bruce JN; Canoll P; Siegelin MD Oncotarget; 2015 Jun; 6(16):14507-21. PubMed ID: 26008975 [TBL] [Abstract][Full Text] [Related]
10. Hypericin, a potential new BH3 mimetic. Doroshenko A; Tomkova S; Kozar T; Stroffekova K Front Pharmacol; 2022; 13():991554. PubMed ID: 36267274 [TBL] [Abstract][Full Text] [Related]
11. Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer. Vallet S; Fan F; Malvestiti S; Pecherstorfer M; Sattler M; Schneeweiss A; Schulze-Bergkamen H; Opferman JT; Cardone MH; Jäger D; Podar K Breast Cancer Res Treat; 2019 Feb; 173(3):585-596. PubMed ID: 30374681 [TBL] [Abstract][Full Text] [Related]
12. Induction of Synthetic Lethality by Activation of Mitochondrial ClpP and Inhibition of HDAC1/2 in Glioblastoma. Nguyen TTT; Shang E; Schiffgens S; Torrini C; Shu C; Akman HO; Prabhu VV; Allen JE; Westhoff MA; Karpel-Massler G; Siegelin MD Clin Cancer Res; 2022 May; 28(9):1881-1895. PubMed ID: 35417530 [TBL] [Abstract][Full Text] [Related]
13. Mechanism of synergy of BH3 mimetics and paclitaxel in chronic myeloid leukemia cells: Mcl-1 inhibition. Song T; Chai G; Liu Y; Xie M; Chen Q; Yu X; Sheng H; Zhang Z Eur J Pharm Sci; 2015 Apr; 70():64-71. PubMed ID: 25596561 [TBL] [Abstract][Full Text] [Related]
14. Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia. Iacovelli S; Ricciardi MR; Allegretti M; Mirabilii S; Licchetta R; Bergamo P; Rinaldo C; Zeuner A; Foà R; Milella M; McCubrey JA; Martelli AM; Tafuri A Oncotarget; 2015 Oct; 6(31):32089-103. PubMed ID: 26392332 [TBL] [Abstract][Full Text] [Related]
16. Targeting intrinsic apoptosis and other forms of cell death by BH3-mimetics in glioblastoma. Karpel-Massler G; Ishida CT; Zhang Y; Halatsch ME; Westhoff MA; Siegelin MD Expert Opin Drug Discov; 2017 Oct; 12(10):1031-1040. PubMed ID: 28712306 [TBL] [Abstract][Full Text] [Related]
18. Dual inhibition of BCL-XL and MCL-1 is required to induce tumour regression in lung squamous cell carcinomas sensitive to FGFR inhibition. Weeden CE; Ah-Cann C; Holik AZ; Pasquet J; Garnier JM; Merino D; Lessene G; Asselin-Labat ML Oncogene; 2018 Aug; 37(32):4475-4488. PubMed ID: 29743589 [TBL] [Abstract][Full Text] [Related]
19. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice. Anstee NS; Bilardi RA; Ng AP; Xu Z; Robati M; Vandenberg CJ; Cory S Cell Death Differ; 2019 Jul; 26(7):1316-1331. PubMed ID: 30470795 [TBL] [Abstract][Full Text] [Related]
20. A novel BH3 mimetic efficiently induces apoptosis in melanoma cells through direct binding to anti-apoptotic Bcl-2 family proteins, including phosphorylated Mcl-1. Liu Y; Xie M; Song T; Sheng H; Yu X; Zhang Z Pigment Cell Melanoma Res; 2015 Mar; 28(2):161-70. PubMed ID: 25324174 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]